Background: Papillary thyroid carcinoma (PTC) with prominent hobnail features is a recently recognized PTC variant. Its histological hallmark is represented by elongated cells showing a high nuclear/cytoplasmic ratio and a hobnail appearance. Few histological studies have been performed showing aggressive clinical and pathological features. Thus, a better patient management might benefit from its early diagnosis on fine needle aspiration (FNA) samples. To date, the FNA cytology of PTC with prominent hobnail features has not been described. Case Report: We retrospectively analyzed the FNA taken from a histologically proven PTC with prominent hobnail features. Although there was a certain degree of morphological overlap with the tall cell variant, some peculiar cytological features were observed. In particular, the novel ‘comet-like’ cell feature could represent the cytological counterpart of the histological hobnailing. V600E BRAF mutation was observed on a matched cytohistological specimen. Conclusion: Further investigation is required to validate our diagnostic criteria, as the recognition of PTC with prominent hobnail features on FNA may prospectively enable its preoperative diagnosis, suggesting more aggressive neck surgery.

Keywords:
Fine needle aspiration, Thyroid, Hobnail papillary thyroid carcinoma, BRAF mutation
1.
Ohori NP, Schoedel KE: Cytopathology of high-grade papillary thyroid carcinomas: tall-cell variant, diffuse sclerosing variant, and poorly differentiated papillary carcinoma. Diagn Cytopathol 1999;20:19–23.
2.
Asioli S, Erickson LA, Sebo TJ, Zhang J, Jin L, Thompson GB, Lloyd RV: Papillary thyroid carcinoma with prominent hobnail features: a new aggressive variant of moderately differentiated papillary carcinoma. A clinicopathologic, immunohistochemical, and molecular study of eight cases. Am J Surg Pathol 2010;34:44–52.
3.
Motosugi U, Murata S, Nagata K, Yasuda M, Shimizu M: Thyroid papillary carcinoma with micropapillary and hobnail growth pattern: a histological variant with intermediate malignancy? Thyroid 2009;19:535–537.
4.
Cibas ES, Ali SZ: The Bethesda System For Reporting Thyroid Cytopathology. Am J Clin Pathol 2009;132:658–665.
5.
Troncone G, Cozzolino I, Fedele M, Malapelle U, Palombini L: Preparation of thyroid FNA material for routine cytology and BRAF testing: a validation study. Diagn Cytopathol 2010;38:172–176.
6.
Solomon A, Gupta PK, LiVolsi VA, Baloch ZW: Distinguishing tall cell variant of papillary thyroid carcinoma from usual variant of papillary thyroid carcinoma in cytologic specimens. Diagn Cytopathol 2002;27:143–148.
7.
Bishop JA, Ali SZ: Hyalinizing trabecular adenoma of the thyroid gland. Diagn Cytopathol 2010;39:306–310.
8.
Casey MB, Sebo TJ, Carney JA: Hyalinizing trabecular adenoma of the thyroid gland: cytologic features in 29 cases. Am J Surg Pathol 2004;28:859–867.
9.
Hirokawa M, Kanahara T, Habara T, Fujimura N, Horiguchi H, Wakatsuki S, Sano T: Dilated rough endoplasmic reticulum corresponding to septate cytoplasmic vacuoles in papillary thyroid carcinoma. Diagn Cytopathol 2000;23:351–353.
10.
Bell CD, Coire C, Treger T, Volpe R, Baumal R, Fornasier VL: The ‘dark nucleus’ and disruptions of follicular architecture: possible new histological aids for the diagnosis of the follicular variant of papillary carcinoma of the thyroid. Histopathology 2001;39:33–42.
11.
Mallik MK, Das DK, Mallik AA, Madda JP, Mirza K, Al-Bishi KK, George SS, Junaid TA: Dark and pale cerebriform nuclei in FNA smears of usual papillary thyroid carcinoma and its variants. Diagn Cytopathol 2004;30:187–192.
12.
Flint A, Davenport RD, Lloyd RV: The tall cell variant of papillary carcinoma of the thyroid gland. Comparison with the common form of papillary carcinoma by DNA and morphometric analysis. Arch Pathol Lab Med 1991;115:169–171.
13.
Sweeney E: Dormant cells in columnar cell carcinoma of the thyroid. Hum Pathol 1995;26:691–693.
14.
Eloy C, Santos J, Soares P, Sobrinho-Simões M: The preeminence of growth pattern and invasiveness and the limited influence of BRAF and RAS mutations in the occurrence of papillary thyroid carcinoma lymph node metastases. Virchows Arch 2011;459:265–276.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.